TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01665430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
Study: NCT00168103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor
Description: Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor
Description: Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
Study: NCT01430507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: Tablet, Low dose, Once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: Tablet, Medium dose, Once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: Tablet, High dose, Once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
Study: NCT01371643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transsphenoidal surgery
Study: NCT03249935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 1 gm PO single dose given as directly observed
Study: NCT02111135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: b-OPV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: b-OPV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: m-OPV2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: m-OPV2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: m-IPV HD

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: t-IPV
Study: NCT04374591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Bicarbonate
Description: Inhalation of Sodium Bicarbonate 8.4% via nebulizer

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Bicarbonate
Description: Inhalation of Sodium Bicarbonate 8.4% via nebulizer
Study: NCT01799239

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test product
Description: The test product consists of an adhesive with a new top film

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product
Description: The test product consists of an adhesive with a new top film

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenSura
Description: SenSura is the CE-marked and commercially available comparator product

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura
Description: SenSura is the CE-marked and commercially available comparator product
Study: NCT00315198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Patch
Description: 2 hours daily patching

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Patch
Description: 2 hours daily patching

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near activities
Description: near visual activities while patching

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distance activities
Description: distance visual activities while patching
Study: NCT04304391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resective Gingival Surgery
Description: Gingivectomy and gingivoplasty:Resective gingival surgical procedured

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resective Gingival Surgery
Description: Gingivectomy and gingivoplasty:Resective gingival surgical procedured

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resective Gingival Surgery
Description: Gingivectomy and gingivoplasty:Resective gingival surgical procedured
Study: NCT03325933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Load/Low Rep Resistance Training
Description: Participants will be prescribed High Load/Low Rep resistance training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Load/High Rep Resistance Training
Description: Participants will be prescribed Low Load/High Rep resistance training.
Study: NCT03933306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Loading dose dexmedetomidine (0.6 mcg/kg for 10 min) administered before anesthesia induction, followed by a continuous infusion (0.5 mcg/kg/h) until 1 hour before the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Loading dose dexmedetomidine (0.6 mcg/kg for 10 min) administered before anesthesia induction, followed by a continuous infusion (0.5 mcg/kg/h) until 1 hour before the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed blood pressure management
Description: Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed blood pressure management
Description: Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine blood pressure management
Description: Blood pressure is maintained according to routine practice, i.e., systolic blood pressure \> 90 mmHg or within ±30% of baseline within intermittent ephedrine or phenylephrine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine blood pressure management
Description: Blood pressure is maintained according to routine practice, i.e., systolic blood pressure \> 90 mmHg or within ±30% of baseline within intermittent ephedrine or phenylephrine.
Study: NCT01104922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: \* Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) \* Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy)
Study: NCT03685643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention - Dating application topic
Description: The intervention will consist of multimedia content to promote the safe usage of dating applications and raise awareness of the risks associated with dating application usage. The intervention will be delivered one-time in a classroom setting.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control - Health and exercise topic
Description: The placebo control will consist of multimedia content regarding exercise and healthy living. It will be delivered once-time in a classroom setting.
Study: NCT02460094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: See Arm Descriptions for dosing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: See Arm Descriptions for dosing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: See Arm Descriptions for dosing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: See Arm Descriptions for dosing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
Study: NCT03378427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate 200 MG [Sivextro]
Description: Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.
Study: NCT03001765

Intervention type: OTHER
Group type: OTHER
Intervention: Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System.
Description: Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
Study: NCT04749511

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Extrambulatory digital PROMs detection
Description: The aim of the study is to investigate the validity of an alternative method of evaluating PROMs in which the questionnaire will be administered to the patient digitally (Google Forms) in an out-of-patient setting.
Study: NCT03609021

Intervention type: PROCEDURE
Intervention: Screening Mammography
Description: Provide bilateral mammogram

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample
Study: NCT02740634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 AV 1451
Description: Tau binding agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 AV 1451
Description: Tau binding agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 PiB
Description: Amyloid binding agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 PiB
Description: Amyloid binding agent
Study: NCT03994510

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and biological assessments - a 5 Years follow-up
Description: During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion.
Study: NCT02858310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 TCR cells
Description: T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 TCR cells
Description: T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study: NCT02616562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Administered subcutaneously (s.c., under the skin) once-weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Administered subcutaneously (s.c., under the skin) once-weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Administered subcutaneously (s.c., under the skin) once-weekly.
Study: NCT03644173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Resilience Empowerment Program including 5 sessions with health coaches
Description: 5 coaching sessions that will take place either in-person or over the phone with a research nurse (RN)-Health Coach. During the sessions, the health coach will focus on introducing the 5 pillars of health and well-being: sleep, activity, purpose, nutrition and resilience. Will introduce breathing techniques participants and will teach patients how to acquire mind-body skills to assist in stress management, learn to thrive by building resilience, feel empowered to manage their health, gain self-care skills to decrease anxiety, pain and nausea naturally, control the stress response and trigger the relaxation response to promote well-being and discover what foods fuel the body in preparation for healing, during recovery and overall health.
Study: NCT02616562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somapacitan
Description: Administered subcutaneously (s.c., under the skin) once-weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin® FlexPro® pen
Description: Administered subcutaneously (s.c., under the skin) once daily.
Study: NCT00403390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand Name Levothyroxine (Synthroid)
Description: Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic formulation of Levothyroxine
Description: Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
Study: NCT03864887

Intervention type: PROCEDURE
Intervention: Oxygen supply of high-low-high procedure
Description: The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2 (phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).

Intervention type: PROCEDURE
Intervention: Oxygen supply of high-low-high procedure
Description: The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2 (phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).

Intervention type: PROCEDURE
Intervention: Oxygen supply of low-high-low procedure
Description: The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).

Intervention type: PROCEDURE
Intervention: Oxygen supply of low-high-low procedure
Description: The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).

Intervention type: DEVICE
Intervention: Optical monitor for hemodynamic parameter.
Description: Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.

Intervention type: DEVICE
Intervention: Optical monitor for hemodynamic parameter.
Description: Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.

Intervention type: DEVICE
Intervention: Optical monitor for hemodynamic parameter.
Description: Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.

Intervention type: DEVICE
Intervention: Optical monitor for hemodynamic parameter.
Description: Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.
Study: NCT04752059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab-deruxtecan 5.4 mg/kg body weight i.v. on day 1 once every three weeks until progression or death
Study: NCT03765983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0084
Description: GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0084
Description: GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide
Study: NCT00540774

Intervention type: DEVICE
Group type: OTHER
Intervention: detection of oral pathology
Description: detection of oral pathology
Study: NCT03228537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrapleural Pneumonectomy
Description: Undergo EPP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleurectomy
Description: Undergo PD

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT03568461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tisagenlecleucel
Description: Tisagenlecleucel is single infusion.
Study: NCT04333030

Intervention type: OTHER
Intervention: questionnaire
Description: Tobacco Use and Risk Questionnaire

Intervention type: OTHER
Intervention: questionnaire
Description: Tobacco Use and Risk Questionnaire

Intervention type: OTHER
Intervention: questionnaire
Description: Tobacco Use and Risk Questionnaire
Study: NCT00794508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADA gene transfer
Description: Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
Study: NCT01775449

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines
Study: NCT04130750

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: treatment of drug screening
Description: Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: treatment of drug screening
Description: Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.
Study: NCT00877162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled crying and routines
Description: Behavioural (teaching and support)
Study: NCT04069338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lithotripter
Description: Patients receive standard of care treatment for their urolithiasis using one of two lithotripter machines

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lithotripter
Description: Patients receive standard of care treatment for their urolithiasis using one of two lithotripter machines
Study: NCT02113618

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cogmed training
Description: Cogmed® working memory training session consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks (i.e. total training time approximately 12,5 hours). In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program adjusts the difficulty of the different tasks trial-by-trial, which allows for each subject to train at a level adjusted to his or her current Working memory capacity

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Training
Description: Standard training session in an online training and also consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level